These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31620867)

  • 1. Risks associated with oral deferiprone in the treatment of infratentorial superficial siderosis.
    Sammaraiee Y; Banerjee G; Farmer S; Hylton B; Cowley P; Eleftheriou P; Porter J; Werring DJ
    J Neurol; 2020 Jan; 267(1):239-243. PubMed ID: 31620867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year observational study of deferiprone in superficial siderosis.
    Kessler RA; Li X; Schwartz K; Huang H; Mealy MA; Levy M
    CNS Neurosci Ther; 2018 Mar; 24(3):187-192. PubMed ID: 29285884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agranulocytosis with deferiprone treatment of superficial siderosis.
    Huprikar N; Gossweiler M; Callaghan M; Bunge P
    BMJ Case Rep; 2013 Aug; 2013():. PubMed ID: 23925681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ten years of iron chelation in a patient with superficial siderosis.
    Levy M
    Neurol Sci; 2019 Sep; 40(9):1947-1949. PubMed ID: 30834458
    [No Abstract]   [Full Text] [Related]  

  • 5. A multi-center safety trial of the oral iron chelator deferiprone.
    Cohen A; Galanello R; Piga A; Vullo C; Tricta F
    Ann N Y Acad Sci; 1998 Jun; 850():223-6. PubMed ID: 9668543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Response of Deferiprone in Infratentorial Superficial Siderosis: a Systematic Review.
    Flores Martin A; Shanmugarajah P; Hoggard N; Hadjivassiliou M
    Cerebellum; 2021 Jun; 20(3):454-461. PubMed ID: 33409768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety profile of the oral iron chelator deferiprone: a multicentre study.
    Cohen AR; Galanello R; Piga A; Dipalma A; Vullo C; Tricta F
    Br J Haematol; 2000 Feb; 108(2):305-12. PubMed ID: 10691860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of deferiprone for the treatment of superficial siderosis: results from a long-term observational study.
    Cossu G; Abbruzzese G; Forni GL; Matta G; Pinto V; Ruffinengo U; Oppo V; Marchese R
    Neurol Sci; 2019 Jul; 40(7):1357-1361. PubMed ID: 30903420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferiprone-associated myelotoxicity.
    al-Refaie FN; Wonke B; Hoffbrand AV
    Eur J Haematol; 1994 Nov; 53(5):298-301. PubMed ID: 7813710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world evidence: Long-term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years.
    Kwiatkowski JL; Thompson AA; Tricta F; Temin NT; Rozova A; Fradette C; Badawy SM
    Am J Hematol; 2024 Jun; 99(6):1031-1039. PubMed ID: 38429922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial.
    Kersten MJ; Lange R; Smeets ME; Vreugdenhil G; Roozendaal KJ; Lameijer W; Goudsmit R
    Ann Hematol; 1996 Nov; 73(5):247-52. PubMed ID: 8959943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators.
    al-Refaie FN; Hershko C; Hoffbrand AV; Kosaryan M; Olivieri NF; Tondury P; Wonke B
    Br J Haematol; 1995 Sep; 91(1):224-9. PubMed ID: 7577638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis.
    Elalfy M; Wali YA; Qari M; Al Damanhouri G; Al-Tonbary Y; Yazman D; Al Hawsawi Z; Karakas Z; Kilinc Y; Yesilipek MA; Badr M; Elsafy U; Salama M; Abdel Rahman Y; Shebl S; Stilman A; Toiber Temin N; Tricta F
    Pediatr Blood Cancer; 2014 May; 61(5):879-84. PubMed ID: 24376176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia.
    Botzenhardt S; Sing CW; Wong IC; Chan GC; Wong LY; Felisi M; Rascher W; Ceci A; Neubert A
    Curr Drug Saf; 2016; 11(2):137-44. PubMed ID: 26419768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferiprone-induced agranulocytosis: 20 years of clinical observations.
    Tricta F; Uetrecht J; Galanello R; Connelly J; Rozova A; Spino M; Palmblad J
    Am J Hematol; 2016 Oct; 91(10):1026-31. PubMed ID: 27415835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infratentorial superficial siderosis: Classification, diagnostic criteria, and rational investigation pathway.
    Wilson D; Chatterjee F; Farmer SF; Rudge P; McCarron MO; Cowley P; Werring DJ
    Ann Neurol; 2017 Mar; 81(3):333-343. PubMed ID: 28019651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferiprone Reduces Hemosiderin Deposition in Superficial Siderosis.
    Kuo PH; Kuo SH; Lo RY
    Can J Neurol Sci; 2017 Mar; 44(2):219-220. PubMed ID: 27788692
    [No Abstract]   [Full Text] [Related]  

  • 18. Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count.
    El-Beshlawy AM; El-Alfy MS; Sari TT; Chan LL; Tricta F
    Eur J Haematol; 2014 Apr; 92(4):337-40. PubMed ID: 24330079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative clinical and radiological recovery in post-operative patients with superficial siderosis by an iron chelator.
    Nose Y; Uwano I; Tateishi U; Sasaki M; Yokota T; Sanjo N
    J Neurol; 2022 May; 269(5):2539-2548. PubMed ID: 34664101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis.
    Tewari S; Tewari S; Sharma RK; Abrol P; Sen R
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Oct; 108(4):e13-9. PubMed ID: 19778731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.